Corcept Therapeutics (CORT) Gross Margin (2012 - 2026)
Corcept Therapeutics (CORT) posted Gross Margin of 98.41% for Q2 2026, little changed sequentially from 98.25% in Q1 2026, and up 18.0% YoY from 83.4% in Q2 2025.
Corcept Therapeutics (CORT) Gross Margin (2012 - 2026) Analysis & Trends
Corcept Therapeutics has reported Gross Margin for 15 years, with the latest figure at 98.41% in Q2 2026.
- Quarterly Gross Margin rose 18.0% year-over-year to 98.41% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 98.3% (down 7.0% YoY) and the FY2025 annual result came in at 98.3%, down 9.0% from the prior year.
- Gross Margin steadied at 98.41% in Q2 2026 per CORT's latest filing, from 98.25% in the prior quarter.
- Over five years, Gross Margin peaked at 98.74% in Q4 2025 and troughed at 97.79% in Q3 2025.
- A 5-year average of 98.48% and a median of 98.52% in 2022 frame the typical range for Gross Margin.
- The widest YoY moves for Gross Margin: up 37 bps in 2025, down 64 bps in 2025.
- Over 5 years, Gross Margin stood at 98.56% in 2022, then grew by 0 bps to 98.61% in 2023, then slipped by 0 bps to 98.37% in 2024, then grew by 0 bps to 98.74% in 2025, then declined by 0 bps to 98.41% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 98.41%, 98.25%, and 98.74% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn | 98.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 98.41% |
| Mar 31, 2026 | 98.25% |
| Dec 31, 2025 | 98.74% |
| Sep 30, 2025 | 97.79% |
| Jun 30, 2025 | 98.23% |
| Mar 31, 2025 | 98.47% |
| Dec 31, 2024 | 98.37% |
| Sep 30, 2024 | 98.43% |
| Jun 30, 2024 | 98.46% |
| Mar 31, 2024 | 98.27% |
| Dec 31, 2023 | 98.61% |
| Sep 30, 2023 | 98.67% |
| Jun 30, 2023 | 98.66% |
| Mar 31, 2023 | 98.69% |
| Dec 31, 2022 | 98.56% |
| Sep 30, 2022 | 98.68% |
| Jun 30, 2022 | 98.73% |
| Mar 31, 2022 | 98.67% |
| Dec 31, 2021 | 98.63% |
| Sep 30, 2021 | 98.67% |